Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

F. Tada · SciRah

Researcher profile · Semantic Scholar

F. Tada

Share profile

F. Tada — researcher profile on SciRah

h-index: 20
Works: 138
Citations: 1,563

Most-cited papers

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients.
M. Persano, M. Rimini, T. Tada, G. Suda +75 more
2023European Journal of Cancer54 citations Open access
Semantic Scholar
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients
M. Rimini, M. Persano, T. Tada, G. Suda +64 more
2023Journal of Cancer Research and Clinical Oncology39 citations Open access
Semantic Scholar
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function
A. Hiraoka, T. Kumada, T. Tada, M. Hirooka +39 more
2023Oncology35 citations
Semantic Scholar
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study
F. Rossari, T. Tada, G. Suda, S. Shimose +70 more
2024Liver Cancer25 citations Open access
Semantic Scholar
Geriatric nutritional risk index as an easy‐to‐use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab
A. Hiraoka, T. Kumada, T. Tada, M. Hirooka +38 more
2023Hepatology Research24 citations Open access
Semantic Scholar
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
M. Rimini, M. Persano, T. Tada, G. Suda +66 more
2023Targeted oncology21 citations
Semantic Scholar
Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients
T. Hatanaka, S. Kakizaki, Atsushi Hiraoka, T. Tada +39 more
2024Alimentary Pharmacology and Therapeutics18 citations
Semantic Scholar
Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice
Atsushi Hiraoka, T. Tada, M. Hirooka, K. Kariyama +44 more
2024Hepatology Research18 citations Open access
Semantic Scholar
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial
T. Tada, T. Kumada, Atsushi Hiraoka, M. Hirooka +39 more
2024Alimentary Pharmacology and Therapeutics17 citations
Semantic Scholar
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings
H. Ohama, Atsushi Hiraoka, T. Tada, M. Hirooka +39 more
2023Oncology16 citations
Semantic Scholar
Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals
Takao Watanabe, Yoshio Tokumoto, K. Joko, K. Michitaka +17 more
2023Scientific Reports16 citations Open access
Semantic Scholar
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib
M. Iavarone, E. Alimenti, T. Tada, S. Shimose +41 more
2023Liver Cancer15 citations Open access
Semantic Scholar
Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: A multicenter analysis
T. Hatanaka, S. Kakizaki, A. Hiraoka, T. Tada +37 more
2023Hepatology Research15 citations
Semantic Scholar
Survival Improvements in Advanced Hepatocellular Carcinoma with Sequential Therapy by Era
Yoshiko Nakamura, M. Hirooka, Atsushi Hiraoka, Y. Koizumi +12 more
2023Cancers14 citations Open access
Semantic Scholar
Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
Kazunari Tanaka, K. Tsuji, Atsushi Hiraoka, T. Tada +40 more
2023Cancers14 citations Open access
Semantic Scholar
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study
M. Persano, A. Casadei-Gardini, T. Tada, G. Suda +71 more
2024Oncology13 citations
Semantic Scholar
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study
T. Hatanaka, S. Kakizaki, Atsushi Hiraoka, T. Tada +43 more
2023Hepatology Research13 citations
Semantic Scholar
α‐FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
F. Rossari, T. Tada, G. Suda, S. Shimose +69 more
2023International Journal of Cancer12 citations Open access
Semantic Scholar
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma
H. Ohama, Atsushi Hiraoka, T. Tada, M. Hirooka +40 more
2024Cancer Reports11 citations Open access
Semantic Scholar
Attempt to Establish Prognostic Predictive System for Hepatocellular Carcinoma Using Artificial Intelligence for Assistance with Selection of Treatment Modality
A. Hiraoka, T. Kumada, T. Tada, H. Toyoda +10 more
2023Liver Cancer11 citations Open access
Semantic Scholar
Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed‐effects regression model approach
T. Hatanaka, S. Kakizaki, Atsushi Hiraoka, T. Tada +42 more
2023Cancer Medicine10 citations Open access
Semantic Scholar
Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study
T. Hatanaka, Y. Yata, Atsushi Hiraoka, T. Tada +44 more
2025Liver international (Print)9 citations
Semantic Scholar
Current management and future perspectives of covert hepatic encephalopathy in Japan: a nationwide survey
Takao Miwa, M. Tsuruoka, Hajime Ueda, T. Abe +32 more
2025Journal of gastroenterology9 citations Open access
Semantic Scholar
Reliable Performance of mALBI Grade‐Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First‐Line Treatment: Comparative Analysis of 13 Risk Models
T. Hatanaka, S. Kakizaki, Atsushi Hiraoka, T. Tada +37 more
2025Journal of Gastroenterology and Hepatology9 citations
Semantic Scholar
Usefulness of aMAP Risk Score for Predicting Recurrence after Curative Treatment for Hepatocellular Carcinoma within Milan Criteria
H. Ohama, A. Hiraoka, F. Tada, Kanako Kato +17 more
2023Oncology9 citations Open access
Semantic Scholar
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate‐stage hepatocellular carcinoma
T. Tada, T. Kumada, Atsushi Hiraoka, M. Hirooka +40 more
2023Liver international (Print)9 citations
Semantic Scholar
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab
M. Persano, M. Rimini, T. Tada, G. Suda +71 more
2024Targeted oncology8 citations Open access
Semantic Scholar
Brief intervention for chronic liver disease patients with alcohol use disorder in a hepatology outpatient unit: Effects and limitations
Nagisa Hara, Atsushi Hiraoka, M. Nakai, M. Shiraki +11 more
2024Hepatology Research8 citations
Semantic Scholar
Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal–gastric varices
F. Tada, A. Hiraoka, T. Tada, M. Hirooka +40 more
2023Journal of gastroenterology8 citations
Semantic Scholar
Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child–Pugh Class B: A Real‐World Study
H. Ohama, Atsushi Hiraoka, T. Tada, Masashi Hirooka +53 more
2026Hepatology Research6 citations
Semantic Scholar
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real‐World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial
Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, Masashi Hirooka +53 more
2026Journal of Gastroenterology and Hepatology6 citations
Semantic Scholar
Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular Carcinoma
Kazunari Tanaka, K. Tsuji, Atsushi Hiraoka, T. Tada +46 more
2025Liver Cancer6 citations Open access
Semantic Scholar
Impact of time‐of‐day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study
A. Naganuma, S. Kakizaki, T. Hatanaka, Atsushi Hiraoka +44 more
2025Hepatology Research6 citations
Semantic Scholar
Neutrophil–Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab
Tomomitsu Matono, T. Tada, T. Kumada, Atsushi Hiraoka +46 more
2025Hepatology Research6 citations Open access
Semantic Scholar
Factors Affecting an Increase in Spleen Volume and Association of Spleen Volume Variation with the Clinical Outcomes of Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma: A Retrospective Analysis
T. Hatanaka, N. Saito, S. Kakizaki, Atsushi Hiraoka +19 more
2024Oncology6 citations
Semantic Scholar
Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab
M. Rimini, B. Stefanini, T. Tada, G. Suda +74 more
2024Liver international (Print)6 citations
Semantic Scholar
Impact of first‐line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
T. Tada, T. Kumada, A. Hiraoka, M. Hirooka +36 more
2023Journal of Gastroenterology and Hepatology5 citations
Semantic Scholar
Simple Scoring System for Esophagogastric Varices Prediction in Hepatocellular Carcinoma Patients without Liver Stiffness Evaluation
Atsushi Hiraoka, F. Tada, H. Ohama, Mai Fukumoto +19 more
2023Oncology5 citations
Semantic Scholar
Lymphocyte–Monocyte Ratio Predicts the Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab
Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, M. Hirooka +53 more
2026Liver international (Print)4 citations
Semantic Scholar
Comparison of Surgical Resection and Radiofrequency Ablation for Early‐Stage HCC Patients With Child–Pugh Class B
T. Hatanaka, S. Kakizaki, Atsushi Hiraoka, T. Tada +14 more
2025Journal of Gastroenterology and Hepatology4 citations
Semantic Scholar
The Current Status of Tumor Markers as Biomarkers in the Era of Immunotherapy for Hepatocellular Carcinoma: Alpha-Fetoprotein Alone Is Not Sufficient
Atsushi Hiraoka, Masatoshi Kudo, T. Tada, T. Hatanaka +44 more
2025Oncology4 citations
Semantic Scholar
Clinical features of patients with hepatocellular carcinoma treated with radiofrequency ablation therapy: developing a simple score to determine the need for immune-adjuvant therapy
F. Tada, Atsushi Hiraoka, Kosuke Nakatani, Kana Matsuoka +22 more
2024Clinical Journal of Gastroenterology4 citations
Semantic Scholar
Development of a Scoring System for Predicting the Difficulty of Bile Duct Cannulation and Selecting the Appropriate Cannulation Method
Taira Kuroda, Hideki Miyata, Kozue Kanemitsu-Okada, Emi Yanagihara +11 more
2024Digestive Diseases and Sciences4 citations
Semantic Scholar
C-reactive Protein-to-Albumin Ratio: A Useful Predictor for Biliary Fistula After Hepatectomy
Takeshi Utsunomiya, Jota Watanabe, Kazunori Tokuda, Y. Ueno +6 more
2024Cureus4 citations Open access
Semantic Scholar
Simple method for predicting muscle volume loss using geriatric nutritional risk index in hepatocellular carcinoma patients
A. Hiraoka, H. Ohama, F. Tada, Yoshiko Fukunishi +17 more
2023Journal of Cachexia, Sarcopenia and Muscle4 citations Open access
Semantic Scholar
Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka, T. Tada, Masashi Hirooka, K. Kariyama +53 more
2026Liver Cancer3 citations Open access
Semantic Scholar
Dynamic changes in the characteristics of hepatocellular carcinoma among Japanese patients: Increasing incidence of cases without liver fibrosis
F. Tada, Atsushi Hiraoka, H. Ohama, Yuka Kimura +23 more
2025Hepatology Research3 citations
Semantic Scholar
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis
T. Hatanaka, Y. Yata, Atsushi Hiraoka, T. Tada +50 more
2025Hepatology Research3 citations
Semantic Scholar
Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct‐acting antiviral agents
H. Ohama, Atsushi Hiraoka, T. Tada, K. Kariyama +13 more
2024Journal of Gastroenterology and Hepatology3 citations
Semantic Scholar
mADRES predicts hepatocellular carcinoma development in patients with hepatitis C virus who achieved sustained virological response
T. Tada, T. Kumada, Atsushi Hiraoka, K. Kariyama +7 more
2024Journal of Gastroenterology and Hepatology3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

H. Ohama×45
Invite
H. Ohama — researcher profile on SciRah
T. Kumada×39
Invite
T. Kumada — researcher profile on SciRah
K. Kariyama×38
Invite
K. Kariyama — researcher profile on SciRah
T. Hatanaka×38
Invite
T. Hatanaka — researcher profile on SciRah

Atsushi Hiraoka

×38

Invite

Atsushi Hiraoka — researcher profile on SciRah

Invite

M. Hirooka — researcher profile on SciRah

E. Itobayashi×37

Invite

E. Itobayashi — researcher profile on SciRah

Invite

K. Tsuji — researcher profile on SciRah

M. Atsukawa×35

Invite

M. Atsukawa — researcher profile on SciRah

Invite

K. Kawata — researcher profile on SciRah

A. Morishita×35

Invite

A. Morishita — researcher profile on SciRah

Invite

J. Tani — researcher profile on SciRah